Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009

References

• Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteremia. Drugs. 2007;67(10):1483–512.
   PubMed Web of Science ®Google Scholar
• Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am. 2009;23(4):965–82.
   PubMed Web of Science ®Google Scholar
• Aksoy DY, Unal S. New antimicrobial agents for the treatment of Gram-positive bacterial infections. Clin Microbiol Infect. 2008;14(5):411–20.
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis. 2005;24(12):826–31.
   PubMed Web of Science ®Google Scholar
• Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis. 2004;10(5):855–7.
   PubMed Web of Science ®Google Scholar
• Ginzburg E, Namias N, Brown M, Ball S, Hameed SM, Cohn SM. Gram positive infection in trauma patients: new strategies to decrease emerging Gram positive resistance and vancomycin toxicity. Int J Antimicrob Agents. 2000;16(Suppl 1):S39–42.
   PubMed Web of Science ®Google Scholar
• Trick WE, Weinstein RA, DeMarais PL, Kuehnert MJ, Tomaska W, Nathan C, et al.. Colonisation of skilled care facility residents with antimicrobial resistant pathogens. J Am Geriatr Soc. 2001;49(3):270–6.
   PubMed Web of Science ®Google Scholar
• Villari P, Farullo C, Torre I, Nani E. Molecular characterization of methicillin-resistant Staphylococcus aureus (MRSA) in a university hospital in Italy. Eur J Epidemiol. 1998;14(8):807–16.
   PubMed Web of Science ®Google Scholar
• Crivellaro S, Leone I, Bianco O, Savoia D. Surveillance of methicillin-resistant Staphylococcus aureus isolated in Torino (northwest Italy). Diagno Microbiol Infect Dis. 2011;69(3):250–7.
   PubMed Web of Science ®Google Scholar
• Marchese A, Gualco L, Maioli E, Debbia E. Molecular analysis and susceptibility patterns of meticillin-resistant Staphylococcus aureus (MRSA) strains circulating in the community in the Ligurianarea, a northern region of Italy: emergence of USA300 and EMRSA-15 clones. Intern J Antimicrob Agents. 2009;34(5):424–8.
   PubMed Web of Science ®Google Scholar
• Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D, Marchese A, et al.. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting. J Chemother. 2006;18(6):589–602.
   PubMed Web of Science ®Google Scholar
• Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents. 2011;37(3):202–9.
   PubMed Web of Science ®Google Scholar
• Monaco M, Sanchini A, Grundmann H, Pantosti A, EARSS Italy S. aureus typing Group. Vancomycin-heteroresistant phenotype in invasive methicillin-resistant S. aureus isolates belonging to spa type 041. Eur J Clin Microbiol Infect Dis. 2010;29(7):771–7.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect. 2005;6(3):282–95.
   Google Scholar
• Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large US database. Crit Care Med. 2006:34(10):2588–95.
   PubMed Web of Science ®Google Scholar
• Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother. 2010;65(6):1126–36.
   PubMed Web of Science ®Google Scholar
• Gonzales-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, Seaton RA, Loeffler J, Chaves RL. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother. 2011;66(4):912–9.
   PubMed Web of Science ®Google Scholar
• Gould FK, Brindle R, Chadwick PR, Fraise AP, Hill S, Nathwani D, et al.. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother. 2009;63(5):849–61.
   PubMed Web of Science ®Google Scholar
• Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al.. ESCMID guidelines on prevention, diagnosis and treatment of infective endocarditis. Eur Heart J. 2009;30(19):2369–413.
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673–81.
   PubMed Web of Science ®Google Scholar
• Fowler VG, Boucher HW, Corey G, Abrutyn E. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.
   PubMed Web of Science ®Google Scholar
• Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation.Clin Microbiol Infect. 2009:15 (Suppl. 6):11–6.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther. 2009;31(9):1936–45.
   PubMed Web of Science ®Google Scholar
• Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007;120:(10Suppl 1) S54–55.
   PubMed Web of Science ®Google Scholar
• Davis SL, McKinnon PS, Hall LM, Delgado G, Rose W, Wilson RF, et al.. Daptomycin versus vancomycin for complicated skin and skin-structure infections: clinical and economic outcomes. Pharmacotherapy. 2007;27(12):1611–8.
   PubMed Web of Science ®Google Scholar
• Weems JJ. The many faces of Staphylococcus aureus infection: recognizing and managing its life-threatening manifestations. Postgrad Med. 2001;110(4):24–629–3135–6.
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al.. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Practice Guidelines. Clin Infect. Dis 2011;52(3):285–92.
   PubMed Web of Science ®Google Scholar
• Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE, et al.. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006;57(4):589–608.
   PubMed Web of Science ®Google Scholar
• Novartis. Cubicin® (Daptomycin). EU summary of product characteristics [Internet]. [Cited 2011 Jul 28]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Summary_for_the_public/human/000637/WC500036050.pdf.
   Google Scholar
• Kullar R, Davis S, Levine D, Zhao JJ, Crank CW, Segreti J, et al.. High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicentre, retrospective study. Pharmacotherapy. 2011;31(6):527–36.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Prakhya A, Hammel JP, Ambrose PJ. Cost-effectiveness of daptomycin and vancomycin in patients with methicillin-resistant Staphyloccus aureus bacteremia and/or endocarditis. Clin Infect Dis. 2009;49(5):691–8.
   PubMed Web of Science ®Google Scholar